Is It Time to Rethink Standard Anticoagulation? Apixaban vs VKA in HeartMate 3 LVADs
Tania Ahuja, Clinical Assistant Professor, Assistant Director of Clinical Pharmacy and Clinical Pharmacotherapy Specialist, shared a post on X:
”Is it time to re-think anticoagulation for HeartMate3 (HM3) LVADs?
2 RCTs and 3 observational studies including 209 patients: 119 in the apixaban group and 90 in the VKA group demonstrating apixaban just as good as VKA and with less.”
Read the full article here.
Title: Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Authors: Andrea Tripoli, Miguel A. Samaniego, Norma N. Gamarra-Valverde, Shivraj Paneer Selvam, Edgardo Kaplinsky, Alejandro Barbagelata, Anna Mara Scandroglio, Juliana Giorgi
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Feb 20, 2026, 17:35Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research